Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how prepaid card loads or patient affordability revenues move quarter to quarter can feel like decoding a payments labyrinth. Paysign鈥檚 disclosures often span hundreds of pages and multiple form types, each packed with regulatory detail on stored-value balances, healthcare co-pay volumes, and settlement risks. If you have ever searched 鈥淧aysign insider trading Form 4 transactions鈥� or wondered why a sudden spike in interchange income shows up deep inside a note to the financials, you know the challenge.
Stock Titan solves that problem. Our AI reads every Paysign quarterly earnings report 10-Q filing, flags segment shifts, and translates revenue recognition footnotes into plain English. AG真人官方-time alerts surface 鈥淧aysign Form 4 insider transactions real-time鈥�, while concise dashboards answer popular questions like 鈥淧aysign annual report 10-K simplified鈥� or 鈥淧aysign 8-K material events explained鈥�. You鈥檒l see at a glance where executives exercised options, how cash settlement fees compare year over year, and which material contracts triggered an 8-K.
Use cases go beyond quick summaries. Analysts download redlined comparisons to spot fee-structure changes; portfolio managers set triggers for 鈥淧aysign executive stock transactions Form 4鈥�; governance teams review 鈥淧aysign proxy statement executive compensation鈥�. Every filing type鈥�10-K, 10-Q, 8-K, DEF 14A, S-8鈥攊s updated directly from EDGAR within minutes. And because our platform keeps the question in mind鈥斺�渦nderstanding Paysign SEC documents with AI鈥� and providing 鈥淧aysign earnings report filing analysis鈥� that matters鈥攜ou save hours and gain confidence before making your next move.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.
Paysign, Inc. (PAYS) 鈥� Form 4 insider activity
Chief Legal Officer Robert Strobo reported two transactions. On 31 Jul 2025 he vested/exercised 64,000 restricted shares (Code 鈥淢鈥�) at $0, lifting his direct holding to 273,811 shares. On 4 Aug 2025 he sold 26,521 common shares in the open market (Code 鈥淪鈥�) at a weighted-average price of $7.0851 (range $6.9976鈥�$7.1530). Post-sale he directly owns 247,290 shares.
The stock grant vests 20 % annually from 31 Jul 2022 through 31 Jul 2027. Derivative table shows 128,000 shares still underlying outstanding awards.
- Net change: +37,479 shares retained.
- Portion sold: 鈮�41 % of newly vested shares.
No earnings, guidance, or other financial disclosures are included.
Paysign, Inc. (PAYS) Form 4 highlights insider activity by CFO Jeffery B. Baker.
- On 07/31/2025 Baker received 64,000 common shares as part of a previously granted restricted stock award; the grant vests 20 % annually from 07/31/2022 through 07/31/2027 and carried a $0 exercise price.
- On 08/04/2025 he sold 30,396 shares at a weighted-average price of $7.0851 (sales occurred within a price range of $6.9976鈥�$7.1530).
Following these transactions Baker directly owns 252,273 common shares and retains derivative rights to 128,000 additional shares tied to the same award. The filing discloses no new option grants, compensation changes or company-specific events and indicates the sale was executed under a Rule 10b5-1 plan. Overall, the activity appears routine, with the executive maintaining a substantial equity stake.
Paysign, Inc. (PAYS) Form 4: Chief Payments Officer & Director Matthew Lanford reported two transactions. On 31-Jul-2025 he vested and acquired 64,000 common shares at a $0.00 exercise price from a 2022 restricted-stock grant (one-fifth vests annually through 31-Jul-2027). On 04-Aug-2025 he sold 26,367 shares on the open market at a weighted-average $7.0851 (range $6.9976-$7.1530). After these trades he directly owns 147,364 common shares and holds 128,000 unvested/derivative shares under the same grant. The filing was submitted as a single-person report and is not 10b5-1 designated.
FAQ
What is the current stock price of Paysign (PAYS)?
What is the market cap of Paysign (PAYS)?
